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1  |  INTRODUCTION
Hepatocellular carcinoma (HCC) is the most com-
mon primary malignancy affecting the liver and is the 
fourth most common cause of cancer- related deaths 
worldwide.1,2 It largely arises from a combination of 
sustained insults to the liver including chronic inflam-
matory changes and necrosis of hepatocytes, fibrosis 
and cirrhosis of the liver, over a median lag time of 
~10– 50 years, depending on the underlying aetiology.3,4 
Traditionally, the highest prevalence of HCC world-
wide mainly affects lower- to- middle income countries 
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Abstract
Cases of hepatocellular carcinoma (HCC) are rapidly rising. This is particularly 
the case in the Western world, as a result of increasing rates of chronic liver dis-
ease, secondary to lifestyle- associated risk factors and the lack of an established 
screening programme for the general population. Traditionally, radical/curative 
treatment options for HCC, including liver transplantation and surgical resection 
are reserved for the minority of patients, presenting with an early stage cancer. 
For patients with advanced disease, Sorafenib and Lenvatinib were, until recently, 
the only licensed systemic treatments, and provided only limited survival benefits 
at the cost of a multitude of potential side effects. Recent scientific advances in 
the field of cancer immunotherapy have renewed significant interest in advanced 
HCC, in order to fulfil this apparent area of unmet clinical need. This has led 
to the success and recent regulatory approval of an Atezolizumab/Bevacizumab 
combination for the first- line treatment of advanced HCC following results from 
the IMbrave150 clinical trial in 2019, with further immune checkpoint inhibi-
tors currently undergoing testing in advanced clinical trials. Furthermore, other 
cancer immunotherapies, including chimeric antigen receptor T- cells, dendritic 
cell vaccines and oncolytic viruses are also in early stage clinical trials, for the 
treatment of advanced HCC. This review will summarise the major approaches 
that have been and are currently in development for the systemic treatment of 
advanced HCC, their advantages, drawbacks, and predictions of where this revo-
lutionary treatment field will continue to travel for the foreseeable future.
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(LMICs) in areas such as East and South- East Asia and 
Africa, although the incidence of HCC is also rising in 
developed areas including the United States, Europe 
and Japan.2,3
Common underlying aetiological factors for HCC in-
clude chronic hepatitis B and/or C virus (HBV/HCV) in-
fection, which still represent the most prevalent causes of 
HCC, especially in LMICs.2 However, other more lifestyle- 
associated causes such as alcohol- related liver disease, 
non- alcoholic fatty liver disease/non- alcoholic steato-
hepatitis (NAFLD/NASH), metabolic syndrome and diet- 
related factors (e.g. aflatoxins), along with genetic factors 
and predispositions (e.g. hereditary haemochromatosis, 
α1- anti- trypsin deficiency, etc.) also play a significant role 
in the pathogenesis of HCC.2,5,6 Such a variety of underly-
ing aetiologies pose both an opportunity and a challenge 
in preventing HCC from a public health perspective and 
in treating and managing the overall rising numbers of 
cases worldwide.2,6 For example, the incidence of cases 
of HCC is rising in the United States mostly as a result 
of increasing levels of alcoholic cirrhosis and NAFLD/
NASH, whereas the incidence of cases in large parts of 
Asia and Africa where chronic HBV and HCV infections 
remain the most common cause are steady or falling due 
to increased uptake of immunisations and use of antiviral 
therapies.5,7,8
Treatment options for HCC are dependent on the stage 
of the disease (Figure 1). These include surgery (includ-
ing curative resection and liver transplantation), radiof-
requency ablation, stereotactic ablative radiotherapy/
stereotactic body radiation therapy, transarterial chemo-
embolisation (TACE), transarterial radioembolisation, 
and systemic targeted therapies including Atezolizumab/
Bevacizumab (immune checkpoint inhibitors [ICIs] that 
are now the established standard of care for advanced 
HCC) and Sorafenib/Lenvatinib (multi- targeted tyrosine 
kinase inhibitors that were previously the standard of care 
for advanced HCC).9– 11 However, the curative treatment 
options for HCC (i.e. surgical) are often only reserved for 
a minority of individuals presenting with localised HCC, 
given delays in presentation and poor performance status/
liver function reserve.9 This is partly due to the fact that 
individuals with HCC are sometimes asymptomatic for 
many months or years, often diagnosed as an incidental 
radiological finding, which is compounded by a lack of ev-
idence for an established generalised cost- effective screen-
ing programme worldwide.1,12
For patients with advanced HCC, licensed systemic 
multi- targeted kinase inhibitors, including Sorafenib and 
Lenvatinib, are sometimes poorly tolerated due to their 
well- characterised side- effect profiles and provide min-
imal benefits in overall survival.14– 17 Moreover, the rates 
F I G U R E  1  Treatment options for hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer (BCLC) staging 
system. Some centres use carefully regulated extended criteria regarding size and number of tumours to select for transplantation. More 
invasive treatments for early stage disease generally have a better prognosis compared to less invasive/palliative treatments for advance 
disease. Adapted from Tellapuri et al.13 PS, performance status; RFA, radiofrequency ablation; TACE, transarterial chemoembolisation
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of recurrence of HCC have historically been shown to be 
~10%– 20% following liver transplantation and are asso-
ciated with a poorer prognosis.18- 21 All of this in combi-
nation leads to a limited 5- year survival rate (~18%) for 
HCC and the need for new and alternative treatments to 
be developed.1,5,22
Cancer immunotherapy has revolutionised the treat-
ment of solid malignancies. Immunotherapy aims to har-
ness an individual's immune system to selectively target 
and kill tumour cells.23,24 This can be achieved via a vari-
ety of mechanisms, as illustrated in Figure 2. This review 
summarises various immunotherapies both currently li-
censed for use in the treatment of HCC and those in the 
stages of preclinical and clinical development.
2  |  IMMUNE CHECKPOINT 
INHIBITORS
The use of ICIs in the treatment of various cancers has 
stimulated marked improvements in the treatment 
of solid malignancies.29,30 ICIs broadly target nega-
tive immune costimulatory modulators expressed on 
the cellular surfaces of both antigen- presenting cells 
(APCs) and T- cells (Table  1). These receptor- ligand 
pairs downregulate the effects of T- cell priming and 
activation, in order to keep the adaptive immune 
system ‘in- check’, with a more minor effect on other 
immune cell types.31,32 Tumour cells manipulate im-
mune checkpoints by upregulating negative costimu-
latory molecules, through their own intrinsic tumour 
activity, or by altering aspects of the surrounding 
tumour microenvironment to enhance immune eva-
sion, tumour progression and spread.33Therefore, 
ICIs aim to block the effects of negative immune 
costimulatory molecules, in order to unleash antitu-
mour activity through promotion and upregulation 
of T- cell priming and activation.31,32 ICIs tip the bal-
ance away from a relative immunosuppressive tu-
mour microenvironment and inhibitory cytokines, 
towards promotion of an immune- mediated response 
against tumour cells and stimulatory cytokine re-
lease, in order to reduce the rate of progression and 
spread of tumour cells (Figure  3).29– 33 There have 
been several licensed ICIs approved for the treat-
ment of cancers including metastatic melanoma, 
non- small cell lung cancer, renal cell carcinoma, and 
colorectal cancer (with microsatellite instability).30 
They primarily target key negative immune costim-
ulatory modulators expressed on either APCs or T- 
cells. These include programmed death cell protein 1 
(PD- 1) (primarily expressed on T- cells), programmed 
death- ligand 1 (PD- L1) (expressed on APCs, other 
immune cells and tumour cells), and cytotoxic T- 
lymphocyte- associated protein 4 (CTLA- 4) (primar-
ily expressed on T- cells).34,35
3  |  MODULATION OF 
MONOCLONAL ANTIBODY 
EFFECTOR FUNCTIONS THROUGH 
FC ENGINEERING
Targeted therapies that selectively bind to and in-
hibit the activity of these co- inhibitory receptors/
ligands predominantly exist in the form of recombi-
nant monoclonal antibodies. For example, Nivolumab 
(a fully humanised IgG4 monoclonal antibody) and 
Pembrolizumab (a humanised IgG4 monoclonal anti-
body) target and bind to PD- 1; Atezolizumab (a fully 
humanised IgG1 monoclonal antibody) targets and 
binds to PD- L1; and Ipilimumab (a fully humanised 
IgG1 monoclonal antibody) targets and binds to CTLA- 
4.9,30,32 The reason why IgG isotypes are selected— 
specifically IgG1, IgG2 and IgG4— are for their long 
half- life, stability and ability to more accurately pre-
dict, and thus provide better control of, downstream 
effector functions to allow for optimal potentiation 
of monoclonal antibody action.36– 38 For monoclonal 
antibodies targeting PD- 1 and PD- L1, they are also 
specifically engineered with single or multiple point 
mutations in their Fc regions to reduce the interac-
tion between the Fc portion of the monoclonal anti-
body and effector cells expressing Fcγ receptors. This 
reduces antibody- dependant cellular cytotoxicity 
(ADCC), antibody- dependant cellular phagocytosis 
and complement- dependant cytotoxicity against host 
immune effector cells.39– 41 For monoclonal antibodies 
targeting CTLA- 4, their primary function is to increase 
ADCC against T regulatory cells (Tregs) (Table 2).39,41
4  |  TREATMENT OF HCC WITH 
ICIs
The liver naturally exists in a relatively immunosup-
pressed state which is heavily regulated by the immune 
system given its physiological role in processing foreign 
materials and first- pass metabolism. This state of im-
munosuppression is hijacked and further exacerbated 
by HCC in order to promote immune evasion and tu-
mour cell survival. Therefore, there exists a potential 
opportunity for ICIs to operate within this niche and 
reverse this process in the tumour, whilst maintaining 
immunosuppression in the background liver in order to 
avoid hepatic autoimmunity. Several clinical trials have 
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previously been undertaken or are currently in progress 
exploring the impact of ICIs in treating HCC at differ-
ent stages and with different underlying aetiologies, 
either as a monotherapy or in various combinations 
(Table 1).42– 49
4.1 | Nivolumab
There have been several clinical trials investigating the use 
of ICIs as monotherapies in the first or second- line setting 
(following failure of Sorafenib/Lenvatinib) for advanced 
F I G U R E  2  The multifaceted actions of cancer immunotherapy including immune checkpoint inhibitors (ICIs), chimeric antigen 
receptor (CAR) T- cells, dendritic cell (DC) vaccines and oncolytic viruses (OVs). Each mode of cancer immunotherapy aims to modulate 
an individual's immune response against tumour cells, either directly or indirectly, through priming and stimulation to enhance the 
autologous effect of antitumour activity towards the tumour and inducing tumour apoptosis/cell death or by modifying the surrounding 
tumour microenvironment to promote immunogenicity. ICIs consist of monoclonal antibodies which target negative immune checkpoint 
costimulatory molecules expressed on both innate and adaptive immune cells (CTLA- 4, programmed death cell protein 1 [PD- 1], 
programmed death- ligand 1 [PD- L1]) and tumour cells (PD- L1). These serve to directly inhibit the negative interaction between tumour cells 
and surrounding host immune cells (through blocking PD- 1/PD- L1 interaction and CTLA- 4) which upregulates T- cell priming in the lymph 
nodes and increases recognition of tumour cells by primed CD8+ T- cells through major histocompatibility complex (MHC) recognition of 
tumour- associated antigens (TAAs) expressed on the surface of tumour cells. Moreover, ICIs also promote antibody- dependent cellular 
cytotoxicity (ADCC) against T regulatory (Treg) cells (which primarily serve to downregulate the immune response against tumour cells) 
and tumour cells themselves through NK cell- dependent ADCC. CAR T- cells are exogenously engineered T- cells expressing a specialised 
CAR that target specific TAAs to promote a controlled positive downstream immune response. DC vaccines consist of isolated autologous 
DCs that are primed in vitro against TAAs before being reintroduced into individuals to promote host T- cell priming. OVs comprise of 
genetically engineered inactivated viruses that preferentially infect tumour cells and upregulate both humoral and cell- mediated immune 
responses25– 28
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HCC.44,46,48,49 These have so far primarily been with mon-
oclonal antibodies that target PD- 1.44,46,48 The CheckMate 
040 (NCT01658878) and CheckMate 459 (NCT02576509) 
trials studied the use of Nivolumab for the treatment of 
histologically confirmed advanced HCC with/without 
HBV/HCV infections.50,51 The CheckMate 040 trial looked 
at the safety and clinical efficacy of different doses of 
Nivolumab in 262 patients (who had previously received 
or not received Sorafenib) in multiple centres/regions 
worldwide. The results found overall objective response 
rates (ORR) of 15% and 20% in the dose- escalation phase 
and dose- expansion phase respectively, with an overall 
median overall survival (mOS) of 15 months in the dose- 
expansion phase. The reduction in tumour burden was 
greatest in those individuals whose disease was not driven 
by viral hepatitis and those who had not previously re-
ceived Sorafenib.50 Moreover, the study also demonstrated 
an acceptable safety and drug tolerability profile which 
led to Nivolumab being granted regulatory approval by 
the United States Food and Drug Administration (FDA) in 
2017 for the treatment of advanced HCC following failure 
of first- line Sorafenib therapy.44,46,47,49,50 This was followed 
by the CheckMate 459 trial which was a multicentre phase 
III trial that directly compared the effects of Nivolumab 
against Sorafenib in advanced HCC. Although the study 
did not achieve a statistically significant difference in 
mOS (HR 0.85, p = 0.0752) (its primary endpoint), clini-
cal benefits of Nivolumab, including mOS and ORR, were 
observed in all subgroups of patients including locally 
advanced and metastatic disease, underlying aetiologies 
(viral hepatitis vs. non- viral hepatitis) and regions (Asia 
vs. non- Asia) compared to Sorafenib, together with an ad-
equate adverse event profile.51 However, following results 
from the CheckMate 459 trial, Nivolumab monotherapy 
for the second- line treatment of advanced HCC was re-
cently withdrawn for use by the FDA due to its failure to 
achieve a statistically significant primary endpoint.52
4.2 | Pembrolizumab
Another PD- 1 inhibitor that has been widely studied for 
the treatment of advanced HCC is Pembrolizumab.42– 49 
The KEYNOTE- 224 (NCT02702414) trial was a multi-
centre nonrandomised phase II trial assessing the clini-
cal safety and efficacy of Pembrolizumab 104 patients 
with advanced progressive HCC of any underlying aeti-
ology and previously treated with Sorafenib (either up to 
failure of treatment or stopped due to drug intolerances/
adverse effects). The study found an ORR of 17% for an 
estimated minimum duration of 9 months, with a man-
ageable adverse event profile.53,54 This subsequently led 
to regulatory approval of Pembrolizumab for second- line 
treatment of advanced HCC by the FDA.42– 47,49 This was 
followed by the KEYNOTE- 240 trial (NCT02702401), a 
randomised phase III trial comparing Pembrolizumab 
to placebo plus best- supportive care following treat-
ment with Sorafenib.55– 57 Similarly to Nivolumab, this 
study did not meet its predefined primary outcome in 
terms of achieving statistical significance (HR 0.781, one- 
sided p = 0.0238), but did show clinical benefits in mOS, 
progression- free survival (PFS) and ORR, particularly in 
the Asian subgroup of patients.55- 58  This is furthered by 
the recent announcement of the preliminary results of the 
KEYNOTE- 394 trial (NCT03062358), which assessed the 
clinical efficacy of Pembrolizumab in Asian patients with 
advanced HCC previously treated with Sorafenib versus 
placebo, indicating statistically significant improvements 
in OS (the primary endpoint), PFS and ORR,59 thus again 
showing potential benefits in this subgroup of patients.
4.3  | Camrelizumab
One of the most recent PD- 1 monoclonal antibodies 
that have been approved for regulatory use in China for 
the treatment of advanced HCC in patients who previ-
ously failed first- line treatment is Camrelizumab.49 This 
was based on the results of a randomised phase II trial 
(NCT02989922) which demonstrated an ORR of 14.7% 
and an mOS of 13.8  months in patients with predomi-
nantly HBV- driven advanced HCC, with follow- up cur-
rently ongoing.60
5  |  PATIENT SELECTION FOR ICI 
MONOTHERAPIES
One of the possibilities as to why both the CheckMate 459 
and the KEYNOTE- 240 trials did not reach their clinically 
predefined primary outcome endpoints was due to the fact 
that both trials were unable to account for the regulatory 
approval of the use of other second- line targeted therapies 
for the treatment of advanced HCC, including Regorafenib 
(a multi- target tyrosine kinase inhibitor) which was li-
censed for use by the FDA in 2017, whilst both clinical tri-
als were still ongoing.42,46,49,51,56 However, certain patient 
subgroups may have benefited from anti- PD- 1 therapy 
more than others.51,56 Significant clinical improvements 
in OS were observed in patients receiving Nivolumab who 
were of Asian ethnicity, positive for HBV/HCV and had 
evidence of metastatic spread,51 and in patients receiving 
Pembrolizumab who was also of Asian ethnicity (exclud-
ing Japan), were HBV- positive and had disease progres-
sion despite Sorafenib.56 Therefore, further work needs 
to be undertaken to better identify molecular biomarkers 
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predictive for patient benefit. This approach was dem-
onstrated in the REACH (NCT01140347) and REACH- 2 
(NCT02435433) trials, where Ramucirumab (a monoclo-
nal antibody targeting the VEGF2 receptor) was shown to 
have increased overall survival benefits in patients with 
advanced HCC who had elevated serum concentrations of 
α- fetoprotein (AFP) (>400  ng/ml),62,63 which ultimately 
led to its regulatory approval by the FDA for second- line 
treatment of advanced HCC.42,43,45– 47,49
One of the more recent ways in which patients are 
potentially stratified based on predictive response to im-
munotherapy is through measuring expression of specific 
molecular biomarkers on tumour cells.34,35 There are cur-
rently no clinically established molecular biomarkers for 
advanced HCC that can predict an outcome in relation to 
treatment with ICIs.42,43,46– 49 One of the most widely stud-
ied predictive molecular biomarkers in PD- 1 and PD- L1 
immunotherapy is the level of expression of PD- L1, which 
has previously been shown to correlate with survival out-
comes in a variety of other cancers, including melanoma, 
non- small cell lung cancer and head and neck squa-
mous cell carcinoma.34,35 However, results from both the 
CheckMate 040 and KEYNOTE- 224 trials demonstrated 
non- statistically significant associations between the lev-
els of expression of PD- L1 and survival outcomes.50,53 
Further research into characterising a potential role for 
PD- L1 expression and establishing other molecular bio-
markers in predicting a treatment response for ICIs in 
HCC is warranted.42,43,46- 49
6  |  MECHANISMS OF ICI 
RESISTANCE IN HCC
Immune checkpoint inhibitor monotherapy in the treatment 
of advanced HCC may be limited by multiple treatment- 
resistance mechanisms.64– 67 These mechanisms can broadly 
be divided into tumour intrinsic factors and tumour extrin-
sic factors. Tumour intrinsic factors include upregulation 
of multiple oncogenic cell signalling pathways (through 
activating mutations), epigenetic modifications, and expres-
sion of cytokines that promote tumour cell proliferation and 
immune evasion.64– 67 Oncogenic cell signalling pathways 
that are upregulated in HCC include receptor tyrosine ki-
nases (EGFR, FGFR, c- MET, VEGFR, etc.), Wnt/ß- catenin, 
MAPK/ERK, PI3K/AKT/mTOR, and the JAK/STAT signal-
ling pathways.68– 72 They are associated with decreased in-
tratumoural infiltration and effector function of T- cells and 
dendritic cells (DCs), and increased T- cell exhaustion.64– 67 
Furthermore, cytokines such as interleukin (IL)- 10 and 
TGF- ß promote tumour cell proliferation and immune eva-
sion through a reduction in the recruitment of APCs and an-
tigen presentation, along with overexpression of alternative 
co- inhibitory cell- surface ligands such as T- cell immunoglob-
ulin domain and mucin domain 3 and lymphocyte- activation 
gene 3.64– 67 The HCC tumour microenvironment is able to 
further promote immune evasion/escape and subsequent tu-
mour cell survival and spread,47,48,73 via mechanisms that are 
both generic to many tumour types and additionally HCC- 
specific mechanisms.74– 77 HCC is a tumour that is charac-
terised by fibrotic changes and chronic inflammation (as a 
result of liver cirrhosis) which creates a physical barrier for 
immune cell infiltration as well as secretion of proinflamma-
tory cytokines that downregulate immune cell function.74– 77 
This is contained in a surrounding microenvironment that 
is largely hypoxic, giving the liver a unique metabolic pro-
file, and immune tolerogenicity (given the large amounts of 
foreign materials that pass through the liver during first- pass 
metabolism), thus further exacerbating a largely immunosup-
pressive environment.74– 77 Cytokines such as IL- 10, TGF- ß, 
VEGF and hepatocyte growth factor are produced by hepatic 
stromal cells including Kupffer cells and hepatic stellate cells 
to reduce the recruitment and activity of tumour- infiltrating 
lymphocytes (TILs) and upregulate the production and activ-
ity of tumour- associated macrophages, Tregs and myeloid- 
derived suppressor cells (MDSCs).48,73– 76 ICI activity and 
efficacy rely on the ability of the host to generate a desired 
immune response against the tumour cells.64– 67 Therefore, 
those tumour cells which express alternative TAAs or have 
a low tumour mutational burden may not respond to ICIs 
from the outset— termed innate/primary resistance.64– 67 
Alternatively, an individual may develop resistance to ICIs 
over time due to the effects of the immunosuppressive tu-
mour microenvironment gradually overwhelming the activ-
ity of ICIs rendering their use redundant— termed acquired/
secondary resistance.64– 67 More work is required to eluci-
date further key cell signalling pathways and better under-
stand the role of the development of tumour resistance in 
advanced HCC, particularly in the context of ICIs.43,47 This 
also provides justification for several clinical trials that have 
been or are currently being undertaken combining different 
treatments for HCC including targeted therapies with exist-
ing locoregional therapies and immunotherapy for advanced 
HCC, which is postulated to reduce the emergence of tumour 
resistance44,47,48 and to improve synergistic benefits.78,79
7  |  PD - 1/PD - L1 INHIBITION 
WITH ANTI- VEGF THERAPY
To date, one of the most successful immunotherapy com-
binations developed to treat advanced HCC has been 
Atezolizumab (a PD- L1 inhibitor) and Bevacizumab 
(a circulating VEGF inhibitor). The IMbrave150 trial 
(NCT03434379) was a global multicentre randomised 
phase III clinical trial that recruited 501 patients and 
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compared OS and PFS (the co- primary endpoints) of 
Atezolizumab and Bevacizumab against Sorafenib.80,81 
There was a 42% reduction in the risk of death with 
Atezolizumab and Bevacizumab in comparison to 
Sorafenib (HR 0.58, p  <  0.001).80,81 mOS was reported 
to be 19.2  months in patients receiving Atezolizumab 
and Bevacizumab compared to 13.4  months in patients 
receiving Sorafenib (HR 0.66, p  =  0.0009).82 mPFS was 
6.8  months (Atezolizumab and Bevacizumab) versus 
4.3 months (Sorafenib) (HR 0.59, p < 0.001).80,81 Benefit 
with the combination therapy was seen in participants 
from all geographical locations, with comparable safety 
profiles.80,81 The most common side effects/adverse events 
were hypertension, fatigue and proteinuria in the partici-
pants receiving Atezolizumab and Bevacizumab.80,81 The 
risk of major oesophageal variceal haemorrhage is a par-
ticular concern to those patients receiving Atezolizumab 
and Bevacizumab and should be actively monitored for 
and treated prior to treatment commencing.80,81 This 
has led to regulatory approval by the FDA, European 
Medicines Agency, and Medicines and Healthcare 
products Regulatory Agency for the use of Atezolizumab 
and Bevacizumab in patients with unresectable or meta-
static HCC who have not received prior systemic ther-
apy.43 Other clinical trials exploring the combination of 
PD- L1 inhibitors with anti- VEGF therapy are currently in 
progress.42,43,45– 47,49 The RESCUE trial (NCT03463876) is 
a phase II clinical trial exploring the safety and efficacy of 
Camrelizumab in combination with Apatinib (a VEGFR- 2 
inhibitor) in patients with advanced HCC who have previ-
ously received Sorafenib,83 and there is also a phase I/II 
clinical trial (NCT04035876) currently underway in China 
assessing Camrelizumab and Apatinib as potential neoad-
juvant therapy for downstaging/bridging of HCC prior to 
curative liver transplantation.
8  |  COMBINATION ICI THERAPY
Combination monoclonal antibody therapies target-
ing some of the most commonly studied immune 
checkpoints are also currently the subject of interest in 
F I G U R E  3  The multitude of effects of immune checkpoint inhibitors that have been developed targeting molecular drivers of 
hepatocellular carcinoma progression. Targets include receptor/ligand pairs found on innate immune cells including natural killer (NK) 
cells (e.g. programmed death cell protein 1 [PD- 1]), adaptive immune cells including T- cells (e.g. PD- 1, cytotoxic T- lymphocyte- associated 
protein 4 [CTLA- 4]), and those found on tumour cells themselves (e.g. PD- L1).
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advanced clinical trials.42– 49 One of the cohort arms of the 
CheckMate 040 trial looked at the safety and tolerability of 
a combination of Nivolumab and Ipilimumab and found, 
along with a positive ORR (32%) and duration of response, 
a manageable safety and toxicity profile which led to regu-
latory approval by the FDA for use in patients with ad-
vanced HCC previously treated with Sorafenib.46,47,49,84 
This led to the development of the CheckMate 9DW trial 
(NCT04039607), a multicentre phase III trial comparing 
the overall survival rates (primary outcome) of a combi-
nation of Nivolumab and Ipilimumab against Sorafenib/
Lenvatinib in patients with advanced HCC who have 
not received prior systemic therapy. Moreover, the 
HIMALAYA trial (NCT03298451) is a multicentre phase 
III trial exploring the safety and efficacy of Durvalumab 
(a PD- L1 inhibitor) both as monotherapy and in combi-
nation with Tremelimumab (a CTLA- 4 inhibitor) versus 
Sorafenib in patients with advanced HCC who have not 
received prior systemic therapy and are also not eligible 
for locoregional therapy.85
9  |  ICIs IN COMBINATION WITH 
LOCOREGIONAL THERAPIES
Whereas some clinical trials have sought to combine the 
use of novel immunotherapy agents, there are also sev-
eral clinical trials that are combining the use of novel ICIs 
with previously established locoregional therapies used in 
the treatment of advanced HCC (as discussed in Section 
1).42,44– 49 One of the rationales behind this is their likely 
complementary mechanisms of actions providing both ad-
ditive and synergistic effects through the direct actions of 
locoregional therapies on tumour cells and potentiation of 
these effects through further stimulation of the immune 
system with the use of ICIs.86– 90 Ablation techniques, radi-
otherapy methods and Doxorubicin (the most commonly 
used chemotherapy agent in TACE) have previously been 
shown to induce immunogenic cell death by apoptosis. 
This stimulates recruitment of DCs to the tumour site and 
upregulates the expression and antigenic presentation of 
TAAs, including PD- 1/PD- L1, following their widespread 
release via apoptotic mechanisms.86– 90 Locoregional 
therapies also induce proinflammatory cytokine release, 
activation and expansion of other innate and adaptive im-
mune cells including NK cells and cytotoxic T- cells, and 
downregulation in the activity of immune suppressive 
cells including Tregs and MDSCs.86– 90 Ongoing clinical 
trials involving combination locoregional and ICI thera-
pies are listed in Table 1.
10  |  ICIs IN COMBINATION WITH 
SYSTEMIC THERAPIES
Multiple clinical trials are currently being undertaken 
evaluating the impact of ICIs in combination with multi- 
targeted tyrosine kinase inhibitors, as potential treatments 
for advanced HCC. The LEAP- 002 trial (NCT03713593) 
is a multicentre, double- blind, randomised phase III trial 
T A B L E  2  A list of the monoclonal antibodies that have been developed or are currently in development that serve as ICIs targeting 
PD- 1, PD- L1 and CTLA- 4 in the treatment of HCC. The majority of them are specifically selected for their antibody class and genetic 
engineering through single or multiple point mutations in their Fc region in order to reduce unwanted off- target or cytotoxic side effects. 
This is primarily due to a reduction (↓) or complete abrogation (↓↓↓) in the interaction between the Fc portion of the monoclonal antibody 
and effector cells expressing Fcγ receptors (FcγRs) which, in turn, reduces antibody- dependant cellular cytotoxicity (ADCC), antibody- 
dependant cellular phagocytosis (ADCP) and complement- dependant cytotoxicity (CDC). Ipilimumab and Tremelimumab both target 
CTLA- 4 which upregulates (↑) ADCC against Treg cells, with no discernible effects on Fc/FcγR interaction (given that they are both wild- 
type monoclonal antibodies) or ADCP/CDC in human models(- ).





Nivolumab PD- 1 IgG4 S228P ↓ ↓ ↓ ↓
Pembrolizumab PD- 1 IgG4 S228P ↓ ↓ ↓ ↓
Camrelizumab PD- 1 IgG4 S228P ↓ ↓ ↓ ↓
Tislelizumab PD- 1 IgG4 S228P/E233P/
F234V/L235A/
D265A/R409K
↓↓↓ ↓ ↓ ↓
Atezolizumab PD- L1 IgG1 N298A ↓↓↓ ↓ ↓ ↓
Durvalumab PD- L1 IgG1 L234F/L235E/
P331S
↓↓↓ ↓ ↓ ↓
Ipilimumab CTLA- 4 IgG1 Wild- type - ↑ - - 
Tremelimumab CTLA- 4 IgG2 Wild- type - ↑ - - 
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evaluating the safety and efficacy of Pembrolizumab 
and Lenvatinib against Lenvatinib as first- line ther-
apy for patients with advanced HCC, with OS and PFS 
being the primary endpoints.91 The COSMIC- 312 trial 
(NCT03755791) is a multicentre, randomised phase 
III trial looking at a combination of Atezolizumab and 
Cabozantinib (a multi- target tyrosine kinase inhibitor), 
along with an arm containing Cabozantinib as mono-
therapy, against Sorafenib in order to evaluate the safety 
and efficacy and their effects on OS and PFS (primary 
endpoints) in patients with advanced HCC who have not 
received prior systemic therapy.92,93 There was also a re-
cent phase Ib trial (NCT03418922) looking at the safety 
and tolerability of Nivolumab and Lenvatinib in patients 
with unresectable HCC. The study found a manageable 
level of adverse events with an overall ORR of 23%.94 
This therapy combination has progressed onto a cur-
rent ongoing phase II trial (NCT03841201) for advanced 
hepatocellular carcinoma.95
11  |  CLINICAL AND 
PRECLINICAL CELLULAR 
THERAPIES
11.1 | Adoptive cell transfer
Another method in which an individual's immune sys-
tem can be harnessed to selectively target and kill tumour 
cells is through ex- vivo stimulation of T- cells against 
TAAs.102– 104 Adoptive cell transfer (ACT) involves identi-
fication of TAAs expressed by a tumour cell and priming 
and expansion of autologous naïve T- cells against these 
specific TAAs, prior to reintroduction into the patient 
(Figure 4).105 In the context of HCC, the majority of ACT 
strategies centre around CD8+ cytotoxic T- lymphocytes, 
which are capable of direct antitumour effects.106– 108 The 
most widely studied TAAs expressed by HCC tumour cells 
are AFP and glypican- 3, although other TAAs are also 
being studied, including New York esophageal squamous 
cell carcinoma 1 (NY- ESO- 1) and melanoma- associated 
antigen 1 (MAGE- A1).106,107
Early iterations of ACT therapies include TILs and 
T- cell receptor (TCR)- engineered T- cells. These broadly 
comprise of endogenously or in vitro- isolated T- cells that 
target specific TAAs which are expanded in vitro before 
being transfused back into a host to generate a systemic 
immune response against tumour cells (Figure  4).102– 105 
A phase I clinical trial exploring the safety of TILs in 15 
patients, who had previously undergone hepatic resec-
tion of HCC, demonstrated successful expansion of TILs 
in 88% of the study population, with an adequate safety 
profile.109 However, issues surrounding the efficacy and 
feasibility of delivering such personalised therapies to pa-
tients remain.102– 105
A more recent approach to ACT therapy involves 
engineering of chimeric antigen receptors (CARs), 
comprising of an extracellular single- chain variable 
fragment that functions as the TAA- recognition do-
main along with costimulatory molecules, a transmem-
brane domain and intracellular signalling domains, 
on T- cells (Figure  4).110– 112 These cells provide a more 
sophisticated approach compared to traditional ACT 
models given the greater ability to control most, if not 
all, aspects of T- cell function. These include recogni-
tion of a specific TAA by the chimeric TCR, to activa-
tion of specific downstream cell signalling pathways, 
and generation of a targeted immune response.110– 112 
CAR T- cells are also able to circumvent any previous 
requirements of the TAA being loaded onto an HLA 
complex in order to achieve T- cell activation (this pro-
cess often being downregulated by tumour cells as part 
of their immune evasion strategy).110– 112 Great strides 
have been made in the development of CAR T- cells used 
to treat cancer and this has been reflected in the recent 
regulatory approval by the FDA of two different CAR 
T- cell therapies for the treatment of acute lymphoblas-
tic leukaemia— Tisagenlecleucel/Kymriah— and dif-
fuse large B- cell lymphoma— axicabtagene ciloleucel/
Yescarta— respectively.110– 112
There are currently multiple ongoing phase I/II clin-
ical trials examining the safety profile and tolerability of 
CAR T- cells in HCC. They broadly target some of the most 
commonly expressed TAAs on HCC tumour cells includ-
ing GPC- 3, AFP, and NY- ESO- 1.106– 108 There is also an 
ongoing phase I/II trial (NCT03013712) currently explor-
ing the safety and efficacy of CAR T- cells that target the 
epithelial cell adhesion molecule antigen expressed on a 
variety of tumour cells including HCC.
One of the main issues surrounding CAR T- cell thera-
pies are the well- characterised but serious adverse effects, 
including cytokine release syndrome and neurotoxicity, 
particularly when CAR T- cells are delivered to individuals 
systemically.110– 112 Moreover, specific concerns surround-
ing the efficacy of systemic CAR T- cell therapy in HCC 
exist, including the unfavourable tumour macroenviron-
ment, characterised by fibrotic stromal changes and cir-
rhosis along with a reduced blood supply, thereby limiting 
penetration by systemic CAR T- cells.106 In an attempt to 
reduce the risk of such unwanted side effects and improve 
the overall efficacy of CAR T- cells, some recent efforts 
have focused on the feasibility and safety of more localised 
delivery of CAR T- cells directly to the site of the tumour, 
primarily through locoregional methods.106
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11.2 | Dendritic cell therapies
The concept of developing a so- called anti- cancer vac-
cine that primes and stimulates the adaptive immune 
system to target and destroy tumour cells has existed 
for over 60  years and is a method that has gained par-
ticular interest and traction over the past 20  years. The 
first anti- cancer vaccine— sipuleucel- T/Provenge— 
secured regulatory approval by the FDA for the treat-
ment of metastatic castration- resistant prostate cancer 
in 2010.113– 116 This strategy broadly involves isolating 
autologous peripheral blood mononuclear cells in vitro, 
expanding the population of DCs through the addition of 
co- stimulating factors including granulocyte- macrophage 
colony- stimulating factor (GM- CSF) and IL- 4, before in-
cubating the mature DCs with autologous tumour lysate 
or with specific TAAs.113– 116 In the case of sipuleucel- T/
Provenge, DCs are incubated with recombinant prostate 
acid phosphatase.113– 116 This procedure generates fully 
primed APCs that are able to present antigenic peptides 
via the major histocompatibility complex on their cell 
surface.113– 116 These can then be infused back into a host 
to stimulate an adaptive cell- mediated immune response, 
characterised by activation and clonal expansion of a vari-
ety of host cells including CTLs that specifically target and 
kill tumour cells.117
It has previously been demonstrated that the surround-
ing tumour microenvironment in HCC is highly immuno-
suppressive.42,44,49 One of the aspects of this relative state 
of immunosuppression is due to an overall reduction in 
the number of DCs found locally within the liver.49 Thus, 
DC therapy represents a theoretical niche whereby sup-
plementing the immune system with primed autologous 
DCs could potentially tip the balance of the immune sys-
tem in favour of the host and promote an overall antitu-
mour immune response.113,115,116
Early- phase clinical trials involving DC vaccines have 
shown them to be generally safe and well- tolerated when 
targeting TAAs expressed on HCC tumour cells, both as 
a primary therapy and as an adjunctive therapy in com-
bination with other established treatments, along with 
being associated with improved overall efficacy and sur-
vival outcomes.118,119 However, it remains unclear as to 
which DC incubation strategy is the most effective for 
treating HCC. Earlier clinical trials focused on incubat-
ing autologous DCs with whole tumour cell line lysates 
derived from the HepG2 cell line, with a level of success 
in terms of safety/tolerability and effects on mOS.120,121 
Controversies exist regarding the most appropriate ad-
ministration route for DC therapy (similar as with CAR 
T- cells) and the most effective therapeutic combinations 
(e.g. surgical resection/curative treatment, locoregional 
therapies, other systemic and/or immunotherapies, 
etc.).122 There have also been multiple clinical trials 
undertaken using a single or a small combination of 
well- established TAAs in HCC, including AFP, GPC- 3, 
MAGE- 1, etc., with mixed results.74,107,108,122 This could 
be due to a lack of adjuvant signalling or tumour escape 
in response to single- antigen vaccination. This has led to 
the development of the HEPAVAC project (www.hepav 
ac.eu), a study looking to identify further novel TAAs 
specific to HCC. The HepaVac- 101 trial (NCT03203005), 
a phase I/II clinical trial is exploring the safety, tolera-
bility and immunogenicity of an adjuvant therapeutic 
anti- cancer vaccine targeting 16 recently identified novel 
peptides from resected HCCs (IMA970A) in combination 
with a novel co- stimulatory agent (CV8102) in patients 
with early- to- intermediate- stage HCC following the fail-
ure of standard treatment.123
12  |  THERAPEUTIC VIRUSES
Viruses are obligate intracellular pathogens that utilise 
unique proteins in their machinery to undertake viral 
replication in target host cells before escaping generally 
by cellular lysis (thereby inducing cell death) in order to 
continue their spread. These principles, in part, have led 
to the creation and evolution of oncolytic viruses (OVs), 
which broadly exert their antitumour effects through 
multiple mechanisms.124– 127 Firstly, OVs often replicate 
preferentially in malignant cells and can be additionally 
genetically engineered to target specific host tumour cells. 
This is achieved either through recognition of and binding 
to TAA cell- surface markers on tumour cells, or by incor-
porating or deleting various genes from the viral genome 
that promote preferential survival and viral replication in 
targeted tumour cells.124– 127 Secondly, OVs promote im-
munogenicity within the host immune system via multi-
ple mechanisms, including the induction of interferons, 
the release and uptake of TAAs by APCs or by being ge-
netically engineered to express genes that upregulate both 
humoral and cell- mediated immune responses.124– 127 The 
field of OVs has previously found success following the 
regulatory approval by the FDA of a modified herpes sim-
plex virus type 1, talimogene laherparepvec, which was 
shown to improve both the rates of objective overall re-
sponse to treatment and mOS in patients with advanced 
melanoma in a phase III clinical trial.128
The most commonly studied OVs for the poten-
tial treatment of HCC in both preclinical and clinical 
studies include adenovirus and vesicular stomatitis 
virus (VSV), both due to their ability to preferentially 
infect HCC tumour cells, along with herpes simplex 
virus, Edmonston strain of the measles virus, Newcastle 
disease virus, and vaccinia virus.108,129,130 One of the 
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leading OVs targeting HCC currently being investigated 
in clinical trials is a modified Wyeth strain of the vac-
cinia virus, JX- 594/pexastigmogene devacirepvec (Pexa- 
Vec), which has been genetically engineered to express 
GM- CSF in order to promote host antitumour activity 
in tumour cells typically expressing high levels of thy-
midine kinase following deletion of the thymidine ki-
nase gene from its viral genome.108,129,131 Unfortunately, 
the TRAVERSE trial (NCT01387555), a phase IIb trial 
comparing intravenous and intratumoural injections 
of Pexa- Vec to placebo as second- line therapy in pa-
tients with advanced HCC who had previously failed 
Sorafenib therapy, did not meet its primary endpoint 
of OS.132 Moreover, the PHOCUS trial (NCT02562755), 
a phase III trial comparing Pexa- Vec with Sorafenib as 
first- line to Sorafenib monotherapy in patients with 
advanced HCC,133 was terminated early following the 
failure of a planned interim futility analysis indicat-
ing that the study was unlikely to meet its OS primary 
outcome.108 Despite these setbacks, other clinical trials 
involving different OVs, including H101 recombinant 
human adenovirus type 5 and VSV expressing human 
interferon beta, are currently ongoing.129
Promotion of an immunogenic environment by OVs 
(as discussed above) also further lends itself to comple-
menting the immunogenic activity of ICIs which has the 
potential to provide an increased and/or synergistic anti-
tumour response.134,135 There are currently several clinical 
trials underway exploring the efficacy of OVs and ICIs in 
combination for the treatment of multiple solid tumour 
sites.134,135 In the context of HCC, OVs hold potential to 
sensitise the immune- tolerant microenvironment and to 
immunologically prime tumours for ICI activity.131,136
13  |  CONCLUSION
Until recently, there were very few successes in the de-
velopment of systemic therapies for advanced HCC. 
However, rapid advances in the field of cancer immuno-
therapy have allowed new targeted therapies to be devel-
oped. For a long period of time, aside from Sorafenib (and 
more recently Lenvatinib), there remained no other first- 
line treatments licensed and available for the systemic 
treatment of advanced HCC. This was until the recent suc-
cess of the IMbrave150 clinical trial which demonstrated 
F I G U R E  4  Approaches to adoptive cell therapy, including chimeric antigen receptor (CAR) T- cells. Earlier approaches relied on 
isolation of endogenous TILs, whereas later approaches rely on inserting genes encoding receptors (T- cell receptor [TCR] or CAR) using 
lentiviral transduction techniques into isolated naïve T- cells. Following in vitro expansion, adoptive cells are then autologously reintroduced 
into patients either systemically or locally directly into the tumour site.
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a clinical benefit for Atezolizumab/Bevacizumab combi-
nation therapy. Other successes within this field include 
the licensing and regulatory approval by the FDA of 
both Pembrolizumab and Nivolumab/Ipilimumab com-
bination as second- line therapies for the treatment of 
advanced HCC. Multiple clinical trials in various stages 
are currently in the pipeline exploring the potential use 
of ICIs both as monotherapies and in combination with 
other established treatment modalities for the treatment 
of advanced HCC.
Whilst ICI immunotherapy leads the field in the devel-
opment of new systemic therapies for treating advanced 
HCC, other immunotherapeutic modalities are rapidly 
progressing, including CAR T- cells, DC vaccines and OVs. 
Much of this work has been aided by a better knowledge 
and understanding of the commonly expressed TAAs 
on HCC tumour cells and of the interplay between tu-
mour cells and their surrounding microenvironment. 
Technological advances have also led to the development 
of the next generation of monoclonal antibodies and CAR 
T- cells, improved personalisation of DC vaccines, and 
better genetic engineering of OVs. These more sophisti-
cated therapies are being clinically tested to enable more 
specific targeting of tumour cells, better control of down-
stream immune responses and a reduction in off- target 
effects. Moreover, several clinical trials are currently un-
derway exploring the role of immunotherapies in the neo-
adjuvant and adjuvant settings in patients with early- and 
intermediate- stage HCC, in an effort to improve treatment 
outcomes and prevent tumour recurrence. Outcomes 
from future clinical trials should also aim to investigate a 
similar role for immunotherapies as downstaging therapy 
in advanced HCC in order to potentially widen access to 
other treatments used for early and immediate- stage HCC 
in these individuals. Future research in this field should 
consider the potential risks of treatment hepatotoxicity 
at the start of the research pipeline. Finally, determining 
clinically useful biomarkers as surrogate measures of im-
munotherapy treatment response and prognosis in HCC 
remains the focus of many in vitro and in vivo studies.
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